BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
SAN RAMON, Calif., Feb. 02, 2016 -- SteadyMed Ltd. (Nasdaq:STDY), a pre-NDA stage specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that Jonathan Rigby, President and Chief Executive Officer will present at the BIO CEO conference on Tuesday, February 9, 2016. Mr. Rigby will provide an overview of the company’s business including its lead drug product candidate Trevyent; a combination of the company’s PatchPump and treprostinil for the treatment of Pulmonary Arterial Hypertension (PAH).
Date: February 9, 2016
Time: 8:30-9:00 am ET
Location: New York, NY
A live audio webcast and archive of the presentation will be available through the Events and Presentations page of the company's corporate website (www.steadymed.com).
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. SteadyMed intends to file an NDA for Trevyent in Q3 2016 and will commercialize Trevyent in the U.S. SteadyMed has licensed certain rights to Cardiome Pharma Corp. for the development and commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
CONTACT: Marylyn Rigby Director, Investor Relations and Marketing 925-272-4999 [email protected]
